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Molecular and cellular mechanisms of aging
in hematopoietic stem cells and their niches
Lei Zhang1, Ryan Mack1, Peter Breslin1,2 and Jiwang Zhang1,3*

Abstract
Aging drives the genetic and epigenetic changes that result in a decline in hematopoietic stem cell (HSC) functioning.
Such changes lead to aging-related hematopoietic/immune impairments and hematopoietic disorders. Understanding how such changes are initiated and how they progress will help in the development of medications that could
improve the quality life for the elderly and to treat and possibly prevent aging-related hematopoietic diseases. Here,
we review the most recent advances in research into HSC aging and discuss the role of HSC-intrinsic events, as well as
those that relate to the aging bone marrow niche microenvironment in the overall processes of HSC aging. In addition, we discuss the potential mechanisms by which HSC aging is regulated.
Keywords: HSCs, Aging, Replication stress
Background
The primary functions of blood cells are transporting
oxygen to tissues by red blood cells (RBCs), antagonizing infections caused by pathogenic agents (macrophages
and neutrophils), maintaining coagulatory hemostasis (platelets), and confronting and responding adaptively to internal and external antigenic affronts (T and
B lymphocyte-mediated immune defense). In the adult
human, ~ 4–5 × 1011 blood cells are lost every day due
to cellular aging or damage. To replenish the loss of
blood cells, approximately the same numbers of blood
cells must be produced from bone marrow (BM) hematopoietic progenitors daily [1–3]. Normal homeostatic
multi-lineage blood cell regeneration, including immunerelated tissue, is primarily maintained through multipotent hematopoietic progenitors (MPPs), which become
exhausted over time, whereas lifetime hematopoiesis and
immunity are maintained by self-renewable hematopoietic stem cells (HSCs) that are localized within specialized BM microenvironments called HSC niches [4–9].
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Like most other tissue-specific stem cells, HSCs are
vulnerable to aging-related stress and gradually lose their
self-renewal and hematopoietic regenerative capacities
(HRC) [10–12]. The process of aging in HSCs is driven
by both cell-intrinsic and extrinsic factors, which lead
to a reduction in blood cell production and impairment
of immune system function [13–16]. Consequently,
elderly populations experience higher incidences of anemia, arterial thrombosis, and myeloid and lymphoid
malignancies (such as age-related clonal hematopoiesis,
myelodysplastic syndromes, acute myeloid leukemia,
chronic lymphocytic leukemia, multiple myeloma and
non-Hodgkin’s lymphoma) [17–19]. In addition, this
population may experience declining adaptive immunity,
autoimmunity, vaccine failure, and experience increased
innate immune-inflammation and susceptibility to infectious diseases [20–23]. Thus, a more in-depth elucidation
of the molecular and cellular mechanisms by which HSC
aging are inter-regulated will not only help in the development of medications for treating and preventing agerelated hematopoietic and immune disorders, but also
provide strategies to advance the quality of life of elderly
populations by reducing the burden of dysfunctional
hematopoiesis and immunity due to aging [24–26].
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Changes in elderly human, monkey, and mouse HSCs
compared to younger adults include: (1) increased numbers; (2) compromised HRC; (3) skewed myeloid differentiation at the expense of T/B lymphocytes; [27–31] (4)
expansion of functionally defective HSCs; and (5) accumulation of clonal hematopoiesis, specifically, genetically
mutant HSCs, due to the selective expansion of age-associated somatic mutant HSCs [10, 11, 13, 32–34]. All of
these changes explain the aging-related alterations seen
in peripheral blood (PB) and tissues, including: (1) attenuated blood cell regeneration in response to radiation or
chemical-induced BM damage; (2) increased percentages
of granulocytes and monocytes, which is always accompanied by a reduced percentage of T/B lymphocytes and
impaired adaptive immunity; (3) reduced anti-infective
activity of neutrophils; and (4) slightly reduced RBC and
platelet numbers [16, 35, 36]. It needs to be mentioned
that all these conclusions regarding the aging of HSCs
were obtained from studies of mouse models, primarily
owing to the availability of relatively specific cell surface
markers that have permitted superior purification and
functional assessment of HSC biology. Nevertheless,
almost all of these conclusions have been verified in other
species, suggesting conserved mechanisms of HSC aging
[37]. Thus, mouse models provide reliable tools to study
the parameters of aging in human HSCs, as age-related
milestones in the murine hematopoietic system reflect
those of humans. C57BL6 mice are commonly used to
study HSCs. It is commonly accepted that 2–6 month-old
mice are young adults, which correspond to 20–39 yearold humans. Mice which are > 20 months-old are considered to be aged mice, corresponding to 65–70 year-old
humans. Almost all conclusions of aged-HSCs from
previous studies were acquired by comparing HSCs collected from > 20 month-old mice to HSCs collected from
2–5 month-old mice. We will focus on the data obtained
from mouse models in this review.

Can the same markers for analysis of young HSCs
be used for aged HSCs?
Significant advances have been made during the past 4
decades in the identification and purification of HSCs in
mice, specifically in C57Bl6 mice. HSCs are fundamentally characterized by specialized molecular markers for
purification and serial transplantation to determine their
capacity to: (1) generate long-term reconstitution of all
blood lineages (multipotency) in irradiated recipient animals; and (2) produce multipotent HSCs themselves in a
process called self-renewal [38–40]. However, all markers
currently in use for HSC analysis were developed using
young HSCs, and we should first determine whether
these markers can be reliably used when studying old
HSCs.
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Development of markers for HSC analysis and purification

Lineage−Sca1+c-Kit+ (LSK) was the first identified constellation of markers for HSC analysis [41], which label
cells containing HSCs and all 4 types of MPPs (MPP1,
2, 3 and 4) [42, 43]. These HSCs give rise to MPPs,
which in turn produce myeloid or lymphoid committed progenitors that subsequently produce all PB and
immune cells. Although MPPs have short-term multilineage hematopoietic reconstitutive activity (ST-HRC),
each MPP type exhibits lineage bias, suggesting that
they possess a lineage-primed feature. Only ~ 2% of LSK
cells have LT-HRC, suggesting that approximately 1 in
50 LSK cells are functional HSCs (fHSCs) [44]. Many
different combinations of markers have been developed to further separate HSCs from MPPs by the addition of more markers in the staining panel for LSK cells
in order to increase the purity of HSCs. For example,
the addition of Flk2 and CD34 permitted Weismann’s
lab to identify HSCs within the LSKCD34−flt3− population [45–47]. By incorporating CD48 and CD150,
Morrison’s lab was able to identify HSCs within the
LSKCD48−CD150+ population [48]. By the incorporation of EPCR, Mulligan’s lab identified HSCs within the
LSKCD34−flt3−EPCR+ population [49, 50]. The use of
Hoechst 33342 staining gave Goodell’s lab the ability to
identify HSCs within a side population, (SP)-LSK cells
[51, 52]. Such combinations of markers identified particular HSCs called phenotypic HSCs (pHSCs), which
are enriched among fHSCs at 20%–40% purity as validated by serial dilution-competitive transplantation
assays. HSCs identified by these different combinations of markers show 70–80% overlap, suggesting that
in addition to marking fHSCs, each panel of markers
also identifies a distinct subset of MPPs. For example,
SP-LSK cells are 100% 
C D34−/lowFlk-2−CD48−, and
+
90% with E
 PCR which can be further separated into
C D150hi, C D150lo and C
 D150− sub-populations [53].
Thus, further combinations of these markers allowed
for increased purity of HSCs [42, 43]. In addition, during the past several years, many HSC-specific reporter
mouse lines were generated by inserting a fluorescent
protein gene under the control of HSC-specific gene
regulators such as Hoxb5-mcherry [54], Fgd5-ZsGr,
[55] α-catulin-GFP, [56] Tie2-eGFP [57], and Pdzk1ip1GFP [9]. In these reporter lines, the fluorescent protein
specifically marks all fHSCs in young mice, which comprise 10–35% of pHSCs. Transplantation studies suggested that fluorescent-protein+ LSK cells are nearly
100% pure fHSCs that have long-term multi-lineage
(LT-ML) HRC. Thus, these HSC reporter mouse strains
provide useful, reliable tools for HSC studies.
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Increase in phenotypic HSC number and decrease
in regenerative capacity during aging

Compared to young adult mice, elderly mice display a significant increase in the number of pHSCs
(~ 17-fold for 
CD34− LSK cells, [27] ~ 15-fold for
−
LSK-CD48 CD150+, ~ 12-fold for CD34−LSK-CD48−
CD150+EPCR+, [58] ~ 5-fold for SP-LSK [52 ]
and ~ 10-fold for CD34−LSK-CD48−CD150+FLK2−)
[59]. Nevertheless, transplantation studies suggested
that the LT-ML HRC of the unpurified BM cells isolated from old mice is increased by only ~ twofold compared to young mice, which is consistent with the ~ 2-fold
increase in functional HSCs determined by standard
serial dilution and competitive transplantation assays [27,
60]. Interestingly, compared to young adults, the 2-fold
increased LT-HRC in old BM cells is better correlated to
the ~ 1.9-fold increase in LSK cells [27, 61, 62]. This suggests that all LT-ML HRC cells are enriched within the
LSK cell population. However, a 2-fold increase in fHSCs
is not consistent with the 10–17-fold increase in pHSCs.
Nevertheless, all fHSCs that have LT-ML HRC are still
within the pHSC population among old mice, regardless of which panel of markers was used, suggesting

a

that fHSCs are enriched within the pHSC population in
old mice. The dramatic increase in pHSCs in old mice
was confirmed by studies of HSC reporter mice such as
Hoxb5-mCherry, Fgd5-ZsGr, Pdzk1ip1-GFP, and Gprc5cEGFP [54–56, 63]. The percentage of fluorescence+ HSCs
is consistently increased in pHSCs of old mice (65–80%)
compared to the percentage of fl
 uorescence+ HSCs in
young animals (10–35%) in these reporter lines. Thus,
the number of fluorescence+ HSCs is increased 25–50fold in old mice compared to young mice. (Fig. 1a). The
increased pHSCs and fl
 uorescence+ HSCs in old mice are
not the result of the induction of HSC markers in MPPs
by inflammatory cytokines in the BM environment of
older animals, because the expression of the fluorescent
protein in the reporter mice cannot be induced by any of
the inflammatory cytokines. Therefore, increased pHSCs
and fluorescence+ HSCs in old animals are unlikely to be
due to increased contamination of MPPs. The markers
that have been used to identify HSCs in young adults can
still reliably label HSCs in the elderly.
Two potential mechanisms explain the inconsistency
of pHSCs, fluorescence+ HSCs and fHSCs in old animals are the following: (1) if the HSCs are functionally

Young adult

Elderly

flu+ HSCs

pHSCs

LSKs ~1.9 fold
pHSCs 10-17 fold
flu+ HSCs 20-50 fold

LSKs
MPPs
pHSCs/LSK:
~5%
flu+ HSCs/pHSCs: 10-35%

b

Young adult

25-30%
65-80%

Elderly

MPPs

MkP
?

Fig. 1 Aging-related changes in pHSCs and flu+ HSCs. a Compared to young mice, LSK cells are increased by 1.9-fold in BM of old mouse pHSCs.
However, HSCs and fl u+HSCs in BM of old mice are expanded by 10–17-fold and 20–50-fold, respectively, owing to the dramatically increased
ratios of pHSCs/LSK and fl u+HSCs/pHSCs. b The reduction in ratios of pHSCs/LSK and flu+HSCs/pHSCs in old mice might be due to the reduced
production of MPPs and/or increased production of MKPs or other committed progenitors which bypass the MPP stage
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homogeneous, as suggested in the early HSC hierarchical model, then the LT-ML HRC of almost all individual
HSCs should be attenuated in older mice; however, (2) if
the HSCs are functionally heterogeneous, then significantly more functionally defective HSCs should accumulate in old animals with only a proportion of HSCs still
maintaining LT-ML HRC. Almost all recent studies support the second mechanism. The significant increase in
the percentage of pHSCs and fluorescence+ HSCs within
the LSK population in old mice is due to differentiation
defects in aged HSCs, which produce fewer MPPs compared to young HSCs. These defects could be either differentiation inhibition or differentiation to committed
progenitors, such as megakaryocyte progenitors (MkPs)
that bypass the MPP stage (Fig. 2).

Increase in lineage‑biased HSCs and functionally
defective HSCs in older animals
Single cell studies demonstrated that HSCs are functionally heterogeneous in terms of both mature cell production and the durability of self-renewal. Compared to
young HSCs, such heterogeneity is significantly amplified
in aged HSCs as determined by in vitro single cell culturing, in vivo single cell transplantation, and single cell
RNA sequencing studies [31, 64–69].

Young adult

Significant increase in lineage‑biased HSCs and functional
defects in HSCs with subtle increase in balanced HSCs
in old mice

In in vitro stromal co-cultures, [27, 58] the behaviors of
HSCs are not the same in terms of their colony-forming
efficiency, cellular components or colony sizes. Most
young HSCs generate large, multi-lineage mixed colonies, while only a small proportion of old HSCs are able
to generate such large multi-lineage clones. Aged HSCs
showed reduced clonogenic efficiency, delayed proliferation and reduced multipotency with myeloid lineage bias
as demonstrated by reduced numbers of colonies, longer
times to form colonies, and more small-sized uni-lineage
or oligo-lineage colonies dominated by granulocytes and
monocytes. Such heterogeneous features of HSCs were
confirmed by single-cell transplantation studies. Based
on myeloid and lymphoid reconstitution ratios, Eaves’
lab classified the LT-HSCs into α- and β- subtypes [66,
70]. Both α- and β- subtypes have robust self-renewal
activity and LT-HRC. The α-HSCs are myeloid-biased
(My-bi) HSCs that produce blood cells with a lower lymphoid/myeloid ratio due to an inherited deficiency in
lymphocyte differentiation [70]. β-HSCs are balanced
(Bala)-HSCs, which produce relatively balanced ratios
of lymphocytes to myeloid cells. The number of α-HSCs
and β-HSCs dynamically changes during development
and aging. Compared to young adults, α-HSCs are

Elderly
Bala-HSCs
pHSCs

Latent-HSCs
Defective HSCs
NR-HSCs

LT-HSCs

pHSCs
>10-fold

Defective
HSCs

Bala-HSCs 2-3-fold (7 in young and 21 in old/106 BM cells)
My-bi HSCs
Latent HSCs (∼82 per 106 BM cells)
Plt-bi HSCs
IT-HSCs ~9-fold
ST-HSCs ~10-fold
IT/ST-Lineage restricted progenitors ~10-20-fold

NR-HSCs ~16-fold
Unidentified cells ~20-fold
Fig. 2 Aging-related changes in fHSCs. Single-cell transplantation studies demonstrate a 2–3-fold expansion of Bala-HSCs, suggesting that
functionally normal HSCs exist in aged mice. A significant number of latent HSCs can be detected only in elderly. In addition, more defective HSCs
and NR-HSCs can be detected in older mice
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significantly increased in old animals, whereas β-HSCs
are slightly increased [70].
The expression of several megakaryocyte–platelet
markers, such as CD150 [31], CD41 [71], CD61 [72]
and Vwf, [68] are increased in aged HSCs. In addition,
Neogenin-1 (NEO1), a multifunctional transmembrane
receptor, is also increased in aged HSCs [59]. By adding
such markers to the well-defined pHSC panels, along
with transplantation functional studies, several labs were
able to largely isolate My-bi HSCs (CD150hi, CD41+,
CD61+, c-Kithi, Vwfint or N
eo1+) from Bala-HSCs
lo
−
−
(CD150 , CD41 , CD61 , c-KitInt, Vwflo or Neo1−) [71,
73]. As is the case with α- and β- HSCs, My-bi HSCs are
significantly expanded in older animals, whereas BalaHSCs are slightly increased [70]. However, all these studies used antibodies against the CD45 isoforms CD45.1
and CD45.2 to distinguish blood cells derived from testing HSCs from blood cells derived from competitor cells
and host cells. Because CD45 cannot be detected in both
RBCs and platelets, all these studies only examined granulocyte, monocyte and lymphocyte contributions to total
HSCs but failed to detect RBC and platelet contributions.
By using HSCs isolated from fluorescent protein+ mice,
Jacobsen’s lab identified platelet-biased (Plt-bi) HSCs.
Such HSCs express high levels of Vwf (Vwfhi), which
generate either platelets alone or platelets with minimal
RBCs and granulocytes. The existence of Plt-bi HSCs was
verified by both single-cell RNAseq assay and noninvasive in situ fate mapping methods in unperturbed mouse
hematopoiesis [4, 5, 7, 74], suggesting that Plt-bi HSCs
are a feature of native hematopoiesis [74, 48, 49]. These
studies demonstrated that Plt-bi HSCs represent a proportion of My-bi HSCs. As is the case with My-bi HSCs,
Plt-bi HSCs are also significantly expanded in old mice.
Studies suggested that at a single-cell level, both Plt-Bi
HSC and My-bi HSC produce a lower output of mature
blood cells than Bala-HSCs in primary transplantation
recipients. However, serial transplantation studies suggest that some Plt-bi HSCs and My-bi HSCs have higher
self-renewal capacity and are able to generate Bala-HSCs
in the recipient BM [75]. This suggests that Plt-bi HSCs
and My-bi HSCs are at the apex of the HSC hierarchy,
upstream of Bala-HSCs. However, due to the lack of reliable assays to further separate Plt-bi HSCs from My-bi
HSCs, the exact relationship between Plt-bi HSCs and
My-bi HSCs has not been delineated. Further study will
need to determine whether Plt-bi HSCs are at the apex
of the HSC-hierarchy, upstream of both My-bi HSCs and
Bala-HSCs, or whether Plt-bi HSCs and My-bi HSCs are
at the same level in the HSC hierarchy.
By doing a more detailed analysis of a relatively large
series of single HSC transplantations, Yamamoto et al.
found that Bala-HSCs are expanded 3-fold in old mice,
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while My-bi/Plt-bi HSCs are expanded > 60 fold. Many
of these My-bi/Plt-bi HSCs displayed multipotent output
(were able to produce all 5 blood cell lineages) in secondary recipients, suggesting a latent type of HSC (also called
MyRP). Such latent HSCs can be identified in BM of old
mice but not in young mice [76]. In addition, significantly
more functionally defective HSCs, such as intermediateterm and short-term HSCs, were detected in old mice.
Furthermore, significantly more non-hematopoietic
reconstituting (NR)-HSCs are detected in old mice. Such
NR-HSCs failed to reconstitute any of the 5 lineages of
blood cells in recipient mice, probably due to a failure of
survival, homing or proliferation during transplantation.
There is also the possibility that some of the NR-HSCs
produce innate immune cells that are localized in tissues
and cannot be detected using current strategies. (Fig. 3).
Taken together, HSCs are highly heterogeneous. The
increased number of pHSCs in old mice is primarily
due to a dramatic increase in My-bi HSCs, Plt-bi HSCs,
latent-HSCs and NR-HSCs, with a subtle increase in
Bala-HSCs. Importantly, the Plt-bi, My-bi and latent
HSCs are less effective in LT-HRC compared to BalaHSCs, as demonstrated in primary recipients, probably
due to their bypassing of the intermediate steps in the
generation of mature progeny. Nevertheless, these lineage-biased HSCs are true fHSCs, not short-term HSCs
or MPPs, because they are able to produce multi-lineage
blood cells in secondary transplant recipients. It also suggests that the ineffective HRC of some of lineage-biased
HSCs is induced by BM environmental influences in old
mice, which can be reversed when transplanted into a
younger BM microenvironment. Functionally defective,
aged HSCs are either dormant or lineage-primed, and
serial transplantation will be required in order to thoroughly study HSC aging [75].
What is the origin of lineage‑biased HSCs and functionally
defective HSCs in old mice?

Increased NR-HSCs in aged mice can be explained by
an increase in apoptosis, senescence or homing defects
due to the accumulation of DNA damage as well as mitochondria and/or other key cellular organelles becoming
defective. However, the precise origin of My-bi and Plt-bi
HSCs in old mice is still being debated. Two hypotheses
have been proposed to explain the origin of My-HSCs
and Plt-Bi HSCs: (1) they might arise from the cell-intrinsic transition of Bala-HSCs to lineage-biased HSCs[29,
31, 77], or (2) they may be generated from the clonal
expansion of preexisting fractions of lineage-biased HSCs
[72, 78, 79] (Fig. 4).
By tracking the mitotic history of HSCs during physiologic aging using H2B-GFP+ long-term-label retaining
(LR) assay, Trumpp’s lab found that HSCs might only
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Young

Old

Bala-HSCs

≤ 4 divisions

b

Young

>4 divisions

Old

≤4 divisions: Bala-HSCs
≤ 4 divisions: My/Plt-HSCs

Bala-HSCs

>4 divisions: Bala-MPPs
>4 divisions: My/Plt-MPPs

My-HSCs
Plt-HSCs
DR-HSCs from fetal?

≤ 4 divisions

>4 divisions

Fig. 3 Models for aging-driven expansion of Plt/My-bi HSCs. Two models were proposed to explain the origin of Plt/My-bi HSCs. a. The Plt/My-bi
HSCs are generated during the Bala-HSC proliferation. b Plt/My-bi HSCs are expanded from pre-existing Plt/My-bi HSCs in young adults

a

Symmetric division

Asymmetric division
b

c

Combined model
Young

Old

Fig. 4 Models for aging-related changes in symmetric and asymmetric division in HSCs. a Asymmetric division of HSCs helps to maintain functional
HSC numbers by distributing stemness factors to one of the daughter cells and differentiation factors to the other. b Symmetric division of HSCs
leads to a gradual dilution of their stemness during each division until it is practically absent. c More HSCs in young mice undergo asymmetric
division; they switch to symmetric division during aging

divide 5 times during the lifespan of a mouse [42]. During each successive division, HSCs progressively acquire
myeloid-primed features at the expense of lymphoid
differentiation potential and self-renewal capacity [80].
Moore’s lab demonstrated that HSCs undergo symmetric division in the BM niche and gradually acquire
My-bi characteristics, which is always companied by an
irreversible reduction in self-renewal capacity. The LRHSCs (≤ 4 divisions) in old mice contain only fHSCs
which still preserve multipotency (with a myeloid bias)

and self-renewal potential, whereas the H2B-GFP− nonLR-HSCs (> 4 divisions) represent functionally defective
HSCs, intermediate HSCs and lineage-restricted progenitors. Thus, non-LR-HSCs have minimal self-renewal
and restricted regenerative capacity [81, 82]. Szade’s lab
found that Neo1 is a better marker for separating My-bi
HSCs from Bala-HSCs. Neo1−Hoxb5+ Bala-HSCs give
rise to N
 eo1+Hoxb5+ My-bi HSCs but the reverse
transition is rarely observed. Using a paired daughtercell assay (PDA), Nakauchi’s lab found that Bala-HSCs
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asymmetrically give rise to Bala-HSCs and Plt-bi HSCs
(MkRPs) or My-bi HSCs, during in vitro short-term incubation [67]. These studies suggest that the My-bi HSCs
are produced by Bala-HSCs and these undergo irreversible loss of stemness (self-renewal and multipotency)
after the fourth division. However, serial transplantation studies suggest that a proportion of Plt-bi HSCs and
My-bi HSCs are latent HSCs which have LT-ML HRC in
secondary transplantation. Although these latent HSCs
are only able to reconstitute very low levels of platelets,
RBCs and granulocytes/monocytes in primary recipients,
they have significantly strong self-renewal capacity and
are able to reconstitute the 5 lineages of hematopoiesis
in secondary recipients [76], suggesting that the lineagebiased feature of aged HSCs is reversible. This conclusion was supported by Jacobsen’s lab, which showed that
Plt-bi HSCs are located at the apex of the HSC hierarchy and give rise to Bala-HSCs during transplantation
[83]. Such a discrepancy among the conclusions of these
studies is primarily due to the different research strategies that were employed. The LR-HSCs in Moore’s studies might contain all real fHSCs including Bala-, My-bi
and Plt-bi HSCs as defined by Nakauchi’s lab, whereas
the non-LR-HSCs only contain ST-HSCs, IT-HSCs and
lineage-restricted progenitors. The Neo1−Hoxb5+ HSCs
in Szade’s study are not pure Bala-HSCs, because they
express myeloid differentiation-related genes compared
to young HSCs. Thus, reliable markers are required to
faithfully distinguish Bala-, My-bi- and Plt-bi-HSCs for
determining the relationship of these 3 types of HSCs in
the hematopoietic hierarchy. Such information is critical
not only for a better understanding of the mechanisms
of HSC aging and hematopoietic diseases, but also for
improving methods for effective ex vivo HSC expansion.
Studies from several other groups suggested that aging
drives the change of the clonal composition of the HSC
compartment but not individual HSCs. My-bi and Pltbi- HSCs already exist in young adults and are expanded
during aging. The biological and functional similarity of My-bi and Plt-bi HSCs from young and old mice
suggest that a clonal expansion of the pre-existing lineage-biased HSCs occurs [67]. These pre-existing lineage-biased HSCs in young adults might be residual fetal
HSCs which have been established as developmentally
restricted HSCs in neonatal BM. The developmentally
restricted HSCs in neonatal BM most likely develop from
early erythromyeloid progenitors (EMPs) generated during the secondary wave of embryonic hematopoiesis in
the yolk sac, because they continuously produce B1 and
γδT innate immune cells [84, 85]. Future studies need to
address whether these pre-existing My-bi HSCs and Pltbi HSCs in young adults develop from yolk sac EMPs or
from AGM-definitive HSCs [86, 87].
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Cell‑intrinsic mechanism of HSC aging
Increased stress due to cell replication, redox stress,
mitochondrial dysfunction, and DNA damage have been
defined as hallmarks of HSC aging. Studies have suggested that HSC-intrinsic changes are induced by proliferation. However, whether HSC-intrinsic changes during
aging are primarily induced by BM niche changes or are
due to niche-independent changes needs to be investigated in the future. In addition, whether aged HSCs regulate the aging of their niches must be evaluated [88].
Proliferation drives HSC aging

In the adult, almost all HSCs are quiescent with respect
to the cell cycle (maintained in 
G0 phase), with only
a small proportion of HSCs (< 5%) at any point in time
entering into the cell cycle for hematopoietic regeneration. Early studies suggested that HSCs divide on average
every 57 days in mice and once every 18 years in humans
[89]. By tracking the cell division-related fluorescence
dilution of fluorescent protein-labeled HSCs, Trumpp’s
and Hock’s groups found that quiescent mouse HSCs
take an average of 128 (56–145) days for one division
under normal physiological circumstances [42, 90]. Thus,
dormant HSCs divide approximately 5 times over the
course of mouse’s lifetime. Recent studies suggested that
the self-renewal and LT-ML HRC of HSCs are negatively
correlated to their divisional history in normal physiological hematopoiesis [82, 91–93]. Therefore, it is speculated
that the major driver of HSC aging is proliferation. Sustaining the quiescent state is pivotal for preserving the
stemness of adult HSCs by maintaining their low metabolic activity, epigenetic landscape and genomic stability.
The increase in HSC number in the elderly is due to the
expansion of functionally attenuated HSCs [23]. Several
potential mechanisms were proposed to explain how cell
divisions attenuate HSC activity, including the induction
of replicative stress, DNA damage, epigenetic landscape
changes, metabolic stress and shorting telomere length
[94–96].
Both symmetric and asymmetric divisions have been
proposed for HSC proliferation. In the symmetric division model, HSCs equally distribute their organelles
and molecular components into the two daughter cells.
In most cases, HSCs undergoing symmetric division
will undergo dilution of their stemness and accumulate
stress-related damage during each division, eventually
becoming exhausted after 4–5 divisions. Only in certain situations, such as fetal HSC development, are both
daughter cells able to maintain self-renewal and multipotency leading to an expansion in their number. However, in the asymmetric division model, HSCs unevenly
distribute their organelles and molecular components,
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[105]. Therefore, HSC fate decisions can be also uncoupled from physical cell division [105]. The exact mechanism by which proliferation induces HSC aging remains
unknown.

leading to cellular polarity. The daughter cells which
receive healthy organelles, such as mitochondria and
lysosomes, [97–100] and self-renewal factors, such as
Cdc42, tubulin and H
 3K36Ac, will maintain HSC activity,
[11, 30, 101–103] while daughter cells receiving impaired
organelles and differentiation factors will lose HSC activity. Thus, HSCs which undergo asymmetric division
should be maintained in the HSC pool permanently. The
progressive loss of cellular polarity in aged HSCs suggests
that more young HSCs undergo asymmetric division
and switch to symmetric division in aged HSCs [71, 72].
The increased number of HSCs in old mice might be a
compensatory mechanism to overcome their loss of HSC
function due to an increase in the frequency of symmetric cell divisions during aging [23] (Fig. 5).
However, some Plt-bi and My-bi HSCs from older animals have more robust self-renewal capacity and can
generate Bala-HSCs in transplantation recipients, suggesting that lineage determination can be uncoupled
from self-renewal [76, 83, 104]. It was found that HSCs
can differentiate into restricted progenitors (including
common myeloid, megakaryocyte–erythroid and premegakaryocyte progenitors) without undergoing cell
division and even before entering S phase of the cell cycle
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DNA damage and genetic mutations in aging HSCs

Compared to proliferative progenitors which use an
error-free homologous recombination (HR) pathway for
DNA damage repair, quiescent HSCs are particularly
vulnerable to DNA damage due to their preferential use
of the error-prone non-homologous end joining (NHEJ)
repair pathway [106]. Approximately, a 2- to 3-fold
increase in accumulated DNA damage in aged HSCs
has been suggested by staining of γH2AX foci, alkaline
comet assay, DNA mutation frequency, and LOH assay
[77, 94, 107, 108], which explains the acquired mutations,
aging-related clonal hematopoiesis and increased risk
of myeloid malignancies in the elderly [109–111]. The
driver role of DNA damage in HSC aging has been suggested by the premature age-related phenotype of HSCs
isolated from mice deficient in DNA repair pathway components [77, 112–114]. DNA damage and mutations in
HSCs might be generated by errors in DNA synthesis
during DNA replication and/or DNA damage induced
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Fig. 5 BM HSC niches. Endosteal/arteriolar niches are localized close to the endosteal region of BM, which are populated by C
 D31hiEmcnhi type-H
ECs and osteogenic-biased MSC-SCs in the arteriolar capillaries at the distal end of the arterial network (transition zone vessels have substantial
branching). Sinusoid niches are localized to the central region of BM and are composed of type-L ECs and adipogenic-biased MSC-SCs. In addition,
MKs, Mφ and Treg cells also function as niche cells to maintain HSC quiescence, retain HSCs within their BM niche, and to protect HSCs from
immune attack. In addition, the adrenergic sympathetic nerve also functions as niche component for HSCs by regulating HSC relocation between
niches
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by endogenous metabolic factors, such as increased ROS
levels or by environmental stresses [115]. DNA damage
diminishes HSC function by inducing a DNA damagerepair response through stimulation of cell cycle checkpoint activation, CD53-p21-mediated cell cycle arrest,
p16Ink [4]-mediated senescence and p53-PUMA-mediated apoptosis [77, 106, 116]. However, cell-intrinsic factors that cause increased DNA damage in aged HSCs are
controversial. Weissman’s lab found that a distinct set of
DNA damage repair proteins are reduced in aged HSCs
compared to young HSCs [108]. However, Passegué’s lab
found an increased number of errors in DNA replication
in aged HSCs [94]. Geiger’s lab demonstrated that young
and aged HSCs are comparable in DNA damage repair,
cell-cycle checkpoint activation and apoptosis, suggesting that increased DNA damage and mutations in aged
HSCs are more likely to accumulate gradually [117].
Replication stress and ribosome biosynthetic stress in HSC
aging

Passegué’s lab found that the increased number of
γH2AX foci in aged HSCs is not associated with DNA
damage due to the lack of co-localization of γH2AX foci
with DNA damage proteins (53BP1 and pCHK1) or DNA
fragmentation (poly-ADP-ribose (PAR) and TUNEL
staining), suggesting that such foci are DNA-damage
independent. However, the increase in γH2AX foci is
strongly associated with increased staining of the single-stranded DNA binding proteins RPA and ATRIP in
proliferative aged HSCs, suggesting a stalled and/or collapsed replication fork-associated γH2AX. The impaired
replication of old HSCs is associated with reduced
expression of mini-chromosome maintenance (MCM)
helicase components. They also observed a long-term
persistence of nucleolar γH2AX in quiescent, old HSCs,
leading to reduced expression of rRNA owing to ineffective H2AX dephosphorylation due to mislocalization of
PP4c. Impaired replication induces the activation of replicative stress in proliferative, aged HSCs and the reduced
rRNA expression induces ribosomal biosynthetic stress
in quiescent aged HSCs. This study suggests that replicative stress and ribosomal stress are potent drivers of a
functional decline in aged HSCs [94]. Consistent with the
results of this study, it was found that ribosomal stress is
one of the key mechanisms common to diseases related
to BM failure [118, 119].
Mitochondrial and metabolic stress in aging HSCs

Although quiescent HSCs have a relatively high concentration of mitochondria compared to hematopoietic progenitors, mitochondria in HSCs are relatively
inactive (morphologically small, round and polarized
with low numbers of swollen cristae) [120, 121]. In
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contrast to hematopoietic progenitors in which mitochondria primarily use the oxidative phosphorylation
(OXPHOS) mechanism to generate energy, HSCs use
mitochondria-independent glycolysis to satisfy their
energy requirements [122]. Although glycolysis generates lower amounts of ATP, such is sufficient for the low
bioenergy needs of quiescent HSCs. Studies suggest
that maintaining mitochondrial health and low metabolic activity is critical for HSC function, [123–125]
and is tightly linked with the cell cycle state of quiescence [126]. Mitochondrial biosynthesis is stimulated
in order to meet increased energy demands when transitioning from G0 to G1. Thus, the proliferation of HSCs
is always associated with the glycolysis-to-OXPHOS
metabolic switch, epigenetic landscape changes and
increased production of ROS [124, 127–131]. ROS
activate mitochondrial biosynthesis and protein translation by inducing the Akt-mTor-PGC-1α/β signaling
pathway, which leads to HSC differentiation [132–138].
In addition, high levels of ROS cause irreversible damage to mitochondria, lipids, proteins and DNA [139].
Much of the damage to mitochondria in HSCs is irreversible. Thus, HSCs employ several surveillance programs to maintain and/or restore their mitochondria
and a low metabolic state in order to preserve their
function. For example, the quality of mitochondria in
HSCs is regulated by fission/fusion and mitophagymediated mitochondrial quality control systems which
segregate and remove the damaged mitochondria
using lysosomal degradation [57, 140, 141]. However,
if the damaged mitochondria cannot be fully removed,
then HSCs will distribute the damaged mitochondria
to one of the mitotic daughters in order to assure that
the healthy mitochondria present in the other daughter cell will preserve the number and function of HSCs
[98, 101, 102]. In addition, the signaling pathways
which mediate nuclear-mitochondrial communication, including 
NAD+-Sirt1-HIF-1α, Sirt7-NRF1 and
Foxo/Sirt3-antioxidants (such as SOD2), also play critical roles in maintaining the low metabolic and inactive
states of mitochondria by regulating redox reactions
and the mitochondrial unfolding protein response
(UPR) [124, 126, 129–131, 142, 143]. Genetic studies
suggested that disruption of any of these quality control
programs and signaling pathways in mitochondria will
induce a premature aged phenotype in HSCs in animals [144]. Compared to young HSCs, down-regulation
of Sirt1, Sirt3 and Sirt7 genes, reduced NAD levels, a
decline in mitochondrial-encoded genes, and increased
Akt-mTor signaling activity are detected in aged HSCs
and are associated with increased mitochondrial protein folding stress, ROS levels and increased symmetric
division. Finally, overexpression of Sirt3 or Sirt7, raising
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nuclear NAD+ levels or inhibition of either mTor or
Cdc42, restore functionality to or even rejuvenate aged
HSCs [101, 102, 135, 145, 146].
Epigenetic deregulation of HSCs during aging

Self-renewal and multipotency are sustained in HSCs
by epigenetic machinery that allows for regulation of
the epigenetic landscape, including DNA methylation
patterns and histone methylation/acetylation profiles,
through maintenance of self-renewal gene expression
and repression of differentiation and lineage-determining
genes [147–151]. The critical role of epigenetic regulators
in promoting proper HSC function is well-documented
in knockout and transgenic animal models [149, 150,
152–154]. For example, Dnmt1 is a DNA methyltransferase enzyme which re-establishes existing DNA methylation patterns during cellular replication by recognizing
hemi-methylated DNA and copying pre-existing DNA
methylation marks from the parental template strand to
the daughter strand [149]. Dnmt3a/3b acts as a de novo
DNA methyltransferase which establishes the new DNA
methylation patterns during development and stem cell
differentiation [152, 155–157]. HSCs in mice decline in
both number and function shortly after deletion of the
Dnmt1 gene, [149, 150, 158] while HSCs are expanded
with enhanced self-renewal in Dnmt3a-knockout mice
and are further enhanced in Dnmt3a/3b double-knockouts [152, 156, 157]. Ten-eleven translocation (Tet)
methylcytosine dioxygenases catalyze the hydroxylation of DNA 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) [159]. Tet2 knockout promotes
self-renewal and expansion of HSCs [160–163]. Polycomb repressor complex 1 (PRC1) and PRC2 repress the
expression of target genes by deposition of the repressive
marks H2AK119ub [1] and H3K27Me [3] [164, 165]. Mice
with deletions of the key components of PRC1 or PRC2,
such as Bmi, Ezh1 and Eed, experience HSC exhaustion
[166–171]. The H3K4 demethylases Kdm5b (Jarid1b) and
Kdm1a (Lsd1), as well as H3K27 demethylases Kdm6a
(UTX) and H3K9 methyltransferase SUV39H1, also play
essential roles in the regulation of HSC function [172–
175]. In addition, histone lysine acetyltransferases Kat6a
(Moz), Kat6b (Morf ) and Kat8 (Mof ) regulate target gene
expression by depositing H3K9ac, H3K23ac/H3K14ac and
H4K16ac, respectively, on the regulatory regions of target
genes. Genetic inactivation of any of these histone acetyltransferases causes HSC exhaustion in mice [176–179].
Accumulated evidence suggests that HSC aging is
regulated by changes in the epigenetic landscape. Comparative studies of epigenetic profiling of young and aged
HSCs reveal a number of epigenetic differences (agerelated epigenetic drift) that underlie the heterogeneous
behavior, lineage-biased feature and clonal expansion
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of HSCs, as well as an increased risk of leukemic transformation [159, 180, 181, 186, 187, 182]. Compared to
young HSCs, there is generally a stable or slight global
gain of DNA methylation and a reduction of 5-hmC in
old HSCs [159, 183]. However, a substantial proportion
of differentially altered DNA methylated regions (DMRs)
in aged HSCs is associated with PRC2 target genes (with
CpG islands), most of which are positive cell cycle regulators and lineage determining factors. These include
increased methylation on the genomic loci associated
with lymphoid and erythroid lineages and reduced methylation on the genomic loci associated with the myeloid
lineage [159]. Although such epigenetic alterations influence changes in gene expression that are associated with
self-renewal and myeloid differentiation of aged HSCs,
they contribute to an aging-related functional decline
and myeloid differentiation skewing of aged HSCs by
regulating gene expression in their differentiated progeny
[71, 82, 184–186]. Compared to young HSCs, there is a
reduction in H4K16Ac levels and a more widespread distribution of H3K4me [3] and H3K27me [3] in aged HSCs
[101]. Most importantly, the aging-related epigenetic
changes of HSCs are associated with a proliferative history, suggesting a proliferation-driven epigenetic memory
loss [184]. Proliferation drives HSC aging by triggering
the switch of HSCs from dormancy and multipotency to
cellular activation and lineage priming through inducing
an epigenetic switch (for example, a switch from Ezh1to-Ezh2 PRC2), [82] downregulating DNA methylation
regulators such as Dnmt1, Dnmt3b and 3 Tet enzymes,
as well as key chromatin modulators such as Bmi, Suz12,
Eed, Kat6b, Jarid1b, Suv39H1 and Sirt1 [82, 92, 148, 159,
187]. In addition, mutations in epigenetic modifiers are
frequently detected in healthy elderly individuals and
these also contribute to epigenetic landscape changes
and the physiological process of aging in HSCs [187].
Consistently, obvious changes in epigenetic chromatin
modifications were detected in aged HSCs. The expression of the microRNA miR-125b, a regulator of HSCs, is
reduced in aged HSCs in both human and mouse. miR125b represses the expression of histone methyltransferase SUV39H1 leading to a global reduction in H3K9Me
[3] and loss of heterochromatin structure. Overexpression of miR-125b and inhibition of SUV39H1 in young
HSCs induces loss of B cell potential, [175] while inhibition of miR-125b and upregulation of SUV39H1 in old
HSCs promotes B cell potential [175].
By comparing gene expression profiling, the DNA
methylation landscape and histone modification patterns in parallel within purified HSCs from old mice and
young mice, Goodall’s lab found that there are not only
more H3K4me [3] peaks but also broader H
 3K4me [3]
peaks across HSC identity and self-renewal genes. Also
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recipients suggest that the Plt-/My-biased commitment
of aged HSCs is largely stimulated by the niche environment. HSC niches also undergo aging-related structural
and functional changes which induce inflammatory challenges to HSCs [72]. Therefore, we might be able to rejuvenate aged HSCs by improving niche cell function and
repressing inflammation in BM [12, 190].

observed was an increase in DNA methylation at transcription factor binding sites associated with differentiation-promoting genes in aged HSCs. Gene expression
profiling demonstrates reduced TGF-β signaling and
increased rDNA expression/ribosome activity in aged
HSCs. This study suggests that epigenetic changes in
aged HSCs might reinforce self-renewal and antagonize
differentiation [159]. The discrepancy between the results
of this study and other studies might be due to the more
purified state of HSCs that were used in the latter study.
The reinforced self-renewal epigenetic landscape changes
in aged HSCs suggested by this study might reflect the
enhanced self-renewal potential of Plt-bi and My-bi
HSCs observed in old animals, while the impaired selfrenewal and lineage-biased epigenetic changes in aged
HSCs detected by other studies might be due to contamination by functionally defective HSCs and MPPs during
analysis.

HSC niches in BM

HSC niches in BM are composed of multiple hematopoietic and non-hematopoietic cells interacting in a complex 3-dimensional architecture to support HSC function
[191]. Three types of BM niches for HSCs have been
described, these being designated the endosteal, [192–
195] arteriolar, [196] and sinusoid niches (Fig. 6) [54, 56,
197, 198]. However, the specific localization of HSCs and
their niches remain difficult to determine and so are still
largely unknown [48, 54, 56, 192–203]. Endosteal niches
are primarily composed of spider-shaped N-cadherin+
osteoblastic (SNO) cells together with an osteopontinrich extracellular matrix within endosteal tissue. SNO
cells are a type of osteogenic mesenchymal stromal cell
(MSC) which maintain the quiescent state of hibernating reserve HSCs and protect such HSCs from the lethal
effects of cancer chemotherapy [193, 204]. Endosteal
niches play such a role probably through Jagged 1-stimulated Notch signaling and osteopontin-mediated

Age‑related HSC niche changes
Although the Bala-HSCs in old mice express many myeloid and platelet genes, they retain normal lymphoid
commitment potential when transplanted into a young
BM microenvironment [31, 59, 188, 189]. Even some
Plt-/My-bi HSCs regain lymphoid differentiation potential upon transplantation into young mice. These reversibility features of aged HSCs in the BM niches of young
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proliferative repression in HSCs [192, 205–208]. In addition, lymphoid-bi-HSCs or B-cell progenitors might be
primarily localized to osteoblastic niches. Osteoblastic MSCs, together with perivascular BM MSCs, support B-lymphopoiesis by producing lymphocyte-specific
cytokines such as Cxcl12 and IL-7 [209–213]. Furthermore, T-reg cells in endosteal niches provide an immuneprivileged microenvironment to protect HSCs from
immune attack [214–216]. Both arteriolar and sinusoid
niches are composed of vascular endothelial cells (ECs)
and surrounding MSCs [197, 203, 217]. However, the ECs
and MSCs in arteriolar and sinusoid niches are not the
same based on their cell surface markers, gene expression patterns and cytokine profiles, suggesting that they
are potentially functionally different [218]. For example,
the ECs in arteriolar niches are VE-cadherin+CD31hig
h
Emcn highSca1 + VEGFR2 + VEGFR3 − ephrin-B2 + Sox17
+
Neuropilin-1+ type-H ECs, while the ECs in sinusoid
niches are VE-cadherin+CD31lowEmcnlowStab2highSca1−
VEGFR3−VEGFR2+ type-L ECs. The MSCs in arteriolar
niches are LepR+CD140αhighNestin-GFPbrightNG2-GFP
bright
Sca1+Myh11+SCFhighCxcl12+ osteo-biased MSCs,
whereas MSCs in sinusoid niches are LepR+CD140αhigh
Nestin-GFPdimNG2lowSca1−SCF+Cxcl12+ adipo-biased
MSCs which are distributed throughout the BM [56, 196,
198, 219–222]. Most arteriolar niches are primarily localized in epiphyseal/metaphyseal BM and the endosteal
region of diaphyseal BM, which might have certain overlaps with endosteal niches. The type-H ECs in arteriolar
niches regulate both angiogenesis and osteogenesis during development. Kunisaki et al. reported that in young
adult BM, most quiescent HSCs are closely associated
with arterioles. It was proposed that arteriolar niches are
characterized by low oxygen concentration that helps to
maintain quiescence in HSCs for hematopoietic preservation, [198, 223] while sinusoid niches maintain their
activated HSCs for active hematopoietic regeneration
[196]. However, several recent studies suggested that
both quiescent and activated HSCs are localized in sinusoid niches and are almost uniformly in contact with vascular VE-cadherin+ ECs and LepR+ MSCs [54, 56]. Such
a discrepancy might be due to the different markers used
to detect HSCs, which could have led to the selective
investigation of different subsets of HSCs in the different
studies.
In addition, macrophages (Mφ), megakaryocytes (MK)
and sympathetic neurons have also been described
as component cells of HSC niches. 
CD169+, DARC/
+
+
CD234 and/or αSMA Mφ are required for retaining quiescent HSCs in 
Nestin+ endosteal/arteriolar
niches. Mφ play such a role by stimulating HSC niche
chemokine/cytokine production, CD82-mediated signaling, Cox2-PGE-2-dependent HSC survival and clearance
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of senescent C
 D62LlowCXCR4high neutrophils [224–229].
Mφ depletion promotes HSC egress into the bloodstream
[224–229]. Sympathetic nerves regulate HSC mobilization and circadian oscillation release by stimulating β2 or
β3 adrenergic receptors (AR) in BM MSCs and osteoblasts in collaboration with Mφs and neutrophils [230–
233]. Furthermore, MKs spatially associate with a subset
of HSCs and maintain HSC quiescence in BM niches.
MKs play such a role by producing TNF-βCXCL4 and
thrombopoietin through collaborating with other niche
cells such as non-myelinating Schwann cells. [16–18, 37,
38] Further study has suggested that most vWF+ Plt-/
My-bi HSCs are localized within sinusoid niches associated with MKs. MKs regulate the proliferation and HRC
of vWF+ Plt-/My-bi HSCs, while NG2+ MSCs in arteriolar niches regulate quiescence and localization of vWF−
Ly/Bala-HSCs [104]. Depletion of MKs in the BM leads
to the proliferation of dormant HSCs and expands Plt-/
My-bi HSCs [104].
Heterogeneity of BM MSCs and ECs

Like HSCs and HPCs, MSCs in BM are also a mixture of
cell populations which are enriched for MSC-stem cells
(MSC-SCs) and early progenitors for adipocytes, osteoblasts, chondrocytes, pericytes and fibroblasts as demonstrated by cell surface markers, gene expression profiles
and cytokine profile studies at single-cell resolution [234–
240]. Only a small proportion of specific MSCs function
as HSCs niches. Such types of MSCs have been defined
as Nestin-GFP+, CD45−CD31−Sca1+CD24+, < 10% of
LepR+ or Pdgfr+Sca1+CD51+ which have the ability to
generate CFU-F and mesenspheres in in vitro culture
and can differentiate into all lineages of MSCs including adipocytes, osteoblasts, chondrocytes, pericytes and
fibroblasts both in vitro and in vivo, suggesting they are
MSC-SCs [196, 203, 219, 241–249]. In addition, different types of hematopoietic progenitors (HPCs) such as B
lymphocyte progenitors and erythroid progenitors also
have their unique niches formed by different types of
MSCs, which produce lineage-instructive cytokines [211,
250, 251]. These studies suggest that MSC-SCs producing self-renewal factors function as niche cells for HSCs,
while distinct types of MSC-progenitors producing lineage-specific factors function as niches for distinct types
of HPCs. Most importantly, like HSCs, the MSC-SCs are
also heterogeneous and might function as niches for different sub-types of HSCs [234, 252, 253]. In further support of this notion, it was found that Nestin-GFPbright and
Pdgfr+Sca1+CD51+ MSC-SCs promote HSC expansion
in vitro by producing the HSC niche-specific cytokines
SCF (KitL), SDF1 (Cxcl12), IL7, angiopoietin 1 (angpt 1)
and adhesive molecular Vcam1 [241, 243, 250]. This ability of MSC-SCs is attenuated upon differentiation and
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can be restored by overexpression of 5 genes (Klf7, Ostf1,
Xbp1, Irf3 and Irf7) which revitalize MSC-SCs [254].
The critical role of BM ECs in HSC regulation has been
well documented. During conditions of homeostasis, specific types of BM ECs are required for maintaining HSCs
by producing the key HSC-specific cytokines Cxcl12,
SCF and Jagged 1/2. During hematopoietic regeneration
and in vitro culture, BM ECs promote HSC expansion by
producing soluble and membrane-bound angiocrine factors including SCF, BMP2/4, IGFBP2, CXCL12, Notch
ligands, Wnt5a, EGF, and pleiotrophin [220, 255–265].
However, the stem cells and progenitors for ECs are not
clearly identified. Whether there are EC-stem cells (ECSCs) that selectively function as niches for HSCs needs
to be determined in the future [248, 249, 266]. A recent
study found that Apelin+ ECs represent 12.4% ± 1.3% of
BM ECs [249, 267]. Such ECs are a subset of type-H arteriolar ECs that express niche factors, including connexin
gap-junction proteins, Notch ligands, and pleiotrophin
(PTN). Apeln+ ECs are required for maintaining HSCs
during steady-state hematopoiesis and regulate hematopoietic regeneration in response to myeloablative injury
[249]. It should be emphasized here that HSCs also produce factors to regulate their own niches. For example,
HSCs produce VEGF-A and angiopoietin which induce
vessel regeneration by stimulating Dll4-Notch signaling in type-H ECs for sprouting angiogenesis and vascular niche regeneration [218, 249]. In addition, type-H
ECs also release angiocrine factors and osteogenic factors which promote proliferation and differentiation of
osteo-MSC-SCs in endosteal/arteriolar niches for vascularization and osteogenesis [218, 221, 249, 266, 268–275].
Thus, it is most likely the case that HSCs, MSC-SCs and
EC-SCs are associated during differentiation and their
progeny work together as niches for each other [276].
Aging of HSC niches

HSC niches in BM undergo significant structural and
functional alterations during aging [277]. Compared
to young mice, although overall vascular density is
increased in BM tissue of aged mice, [221, 230] arteries and arterioles are decreased in their length and
diameter and the vessels in aged BM display a disorganized orientation. In particular, the vessels containing type-H ECs that bridge the arteriolar and sinusoid
capillaries are significantly reduced [278]. However, the
sinusoid vasculature is less affected and small capillaries containing type-L ECs (< 6 mm in diameter) in the
central BM are expanded [190, 278]. The retraction of
endosteal regions and reduced transitional zone vessels in these regions, along with expanded small capillaries in the non-endosteal (central) region, suggest a
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reduction in endosteal/arteriolar niches with a reduced
effect on sinusoid niches [190]. The age-related reduction in endosteal/arteriolar niches is associated with
the downregulation of Notch ligands Dll1 and Dll4 in
type-H ECs, suggesting aging-related impairment of
Notch signaling in the arteriolar niche [236, 278, 279].
In addition, due to the lack of recovery of expression of
the endothelial Notch ligand Jag2 after chemotherapy
in old sinusoid ECs, such drug treatment causes longterm hematopoietic disruption in the elderly owing to
the attenuated recovery of sinusoidal niches [81, 278].
The results of these studies suggest that altered Notch
signaling critically contributes to the aging-related
defects of both endosteal/arteriolar and sinusoid niches
of HSCs [81] (Fig. 7).
Consistent with structural changes in BM niches,
the MSCs and ECs in old BM display significant
qualitative and quantitative changes. Although the
absolute numbers of BM MSCs and ECs are not significantly altered, [280–284] the numbers of NestinGFPbrightPDGFRβ+NG2+ MSCs and 
CD31hiEmcnhigh
type-H ECs in endosteal regions are reduced in the aged
BM, while LepR+Nestin-GFPlow MSCs and CD31loEmcnlo
type-L ECs in the central BM are not reduced [81, 190,
230]. The qualitative changes of MSCs in older BM is
demonstrated by: (1) reduced capacity of colony-forming
unit fibroblasts (CFU-F) and mesenspheres in vitro; (2)
reduced expression of HSC niche factors; [230] and (3)
reduced osteogenesis and increased adipogenesis that is
associated with lower osteopontin secretion to the extracellular matrix [194, 285]. As a consequence, an increase
in adipocytes is a common feature of BM in the elderly
and is associated with an increased risk of osteoporosis
and bone fractures [247, 286, 287]. Most studies suggested that adipocytes in the BM reduce hematopoietic
reconstitution [286–288]. The aging-related contraction
of endosteal BM and reduced osteopontin contained in
the matrix in the elderly explain the myeloid skewing
phenotype owing to the reduction in lymphocyte-specific
niches [251, 289–292]. Supporting this idea, it was found
that the decline in osteopontin accelerates HSC divisions
during aging, and treatment with thrombin-cleaved osteopontin partially reverses the age-associated phenotype
of HSCs [194, 254]. The aging-related structural changes
of BM niches are also associated with functional declines
of vascular ECs as demonstrated by decreased angiogenic
potential. Thus, the vascular niche in old mice shows
increased leakiness and ROS levels. In addition, ECs and
MSCs isolated from older mice show reduced ability to
support the expansion of LT-HSCs in co-culture compared to their younger counterparts [293]. It was found
that expression of Dll4 in vascular ECs prevents myeloid
skewing of HSCs [236].
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Fig. 7 Mechanism of HSC aging. HSCs undergo niche-driven and proliferation-associated changes during aging. Proliferation induces multiple
stresses on HSCs including replication, ribosome biosynthesis, DNA damage, as well as metabolic and epigenetic stresses. Such stresses attenuate
the self-renewal capacity of HSCs by inducing p53-dependent/independent senescence/apoptosis and promote lineage-biased differentiation by
inducing platelet/myeloid genes and repressing lymphoid genes. Aging of HSC niches promotes the switch from asymmetric division to symmetric
division in HSCs and impairs the self-renewal of HSCs due to a reduction in key niche factors including SCF, Cxcl12, IL7, and Notch ligands. In
addition, the accumulation of MKs, M, plasma cells (PCs), aging-associated B cells, and MDSCs, which is primed by inflammatory mediators,
promotes the Plt/My-biased phenotype in HSCs through the production of inflammatory cytokines such as CCL5, IL1β, TNFα, IFN-γ, Wnt5 and TGFβ

Changes in HSC‑niche interactions during aging

More HSCs in aged mice are localized at some distance from the endosteal bone surface, arterioles, Nestin-GFPhigh cells and/or MKs in situ. However, HSC
distance from sinusoids and Nestin-GFPlow cells appears
unchanged [81, 190, 230]. Significantly more HSCs egress
into the circulation in old mice [294]. Upon transplantation, aged HSCs display homing defects which correlate with increased HSCs being localized away from the
endosteum [101]. Long-term labeling retention assays
demonstrate that the most quiescent LR-HSCs with the
highest HRC and cellular polarity reside individually and
predominantly in Nestin-GFPlow perisinusoidal niches in
old mice. In contrast, the non-LR-HSCs are largely apolar and were found more frequently in clusters, [278, 279]
which are located significantly further away from the vasculature [18, 19]. These studies suggest that due to the
contraction of endosteal/arteriolar niches during aging,
perisinusoidal niches protect HSCs from aging stresses in
the BM of aged mice [81].
In addition to MSCs and ECs, many other types of
niche cells, including MKs, Mφ and sympathetic nerves,
also undergo significant aging-related changes. For

example, the numbers of MKs and Mφ are increased
in the BM of old animals; however, the HSC supportive function of these cells has undergone decline in
old BM. More HSCs in old animals are localized away
from MKs [190, 230] The MKs in aged mice have abundant pseudopodial extensions and fail to maintain HSC
quiescence [190]. The aged BM Mφs display impaired
ability to clear senescent neutrophils. In addition, aged
BM Mφs cause elevated IL-1β and promote the expansion of Plt-/My-bi HSCs at the expense of Bala-HSCs
[295]. The response of BM MSCs to adrenergic signaling is altered due to the switch of β3-AR to β2-AR
expression. Such a signaling switch also contributes to
HSC aging [296]. Furthermore, age-associated senescent B cells (ABCs), myeloid-derived suppressor cells
(MDSCs) and plasma cells are increased in old BM.
Both MDSCs and ABCs produce elevated concentrations of pre-inflammatory cytokines like CCL5, IL-1,
TNFα and interferon-γ, whereas plasma cells induce
the production of inflammatory factors from BM MSCs
[297–301]. All of these inflammatory cells also contribute to enhanced myelopoiesis in aging BM [302].

Zhang et al. J Hematol Oncol

(2020) 13:157

Conclusions
Significant progress has been made during the last
30 years in the study of aging-related changes in HSCs
and their niches. This progress includes: (1) development
of reliable panels of antibody markers and genetic animal
models for analysis of HSCs in both young and old mice;
(2) improved ability for the examination of functional
HSCs and determination of the heterogeneity of HSCs by
using single-cell transplantation and single-cell sequencing; (3) improved ability to more precisely detect HSC
localization in the BM and the structure/components
of HSC niches through the use of deep imaging quantification and 3-dimensional microanatomical analysis of
the BM niche [303]. Such technical improvements have
allowed the examination of the age-dependent structural
changes of HSC niches at the resolution of single cells;
[221, 278] (4) investigation of the aging-associated accumulation of several types of mature hematopoietic cells
and how they impact HSC aging; and (5) identification
of potential niche factors and signaling pathways that are
associated with HSC aging [268]. All these achievements
not only improve our ability to understand the cellular/
molecular mechanisms by which physiological aging of
the hematopoietic/immunologic system is regulated, but
will help us to elucidate the pathogenesis of aging-related
hematopoietic disorders.
While all of these foregoing advances are significant,
there are still many aspects of this topic that need to
be further investigated. First, several conflicting results
have been reported with regard to quiescent HSCs,
active HSCs and their niches, owing to the different
protocols that have been used in the identification of
HSCs in situ. For example, some studies used CD11b
and CD41 in their lineage cocktails and thus excluded
many of the aged HSCs, whereas others did not include
these antibodies in their cocktails. Second, the conclusions concerning aging-related changes in HSCs were
not always consistent owing to the different standards
of purity of HSCs and different pre-conditioning protocols that were used for transplantation functional studies. For example, most research protocols use radiation
for pre-conditioning recipient animals in preparation
for HSC transplantation. However, it must be kept in
mind that this induces significant inflammation and
might preferentially stimulate the Plt/My-bi feature in
the HSCs being studied. Several recent reported studies
used busulfan or anti-Kit antibodies for pre-conditioning of recipient mice, resulting in minimal inflammation [189]. Compared to radiation, HSCs in recipients
pre-conditioned by either of the latter two regimens
are more balanced in multi-lineage engraftment [189].
Thus, in the future, the Plt-/My-bi feature of aged HSCs
needs to be further verified using less inflammatory
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pre-conditioning assays in order to exclude the possibility that this feature is induced by the inflammatory
BM environment in recipients. In addition, different
standards were used for evaluating LT-ML HRCs. For
example, most previous studies examined only three
lineages for engraftment, which failed to detect Plt-bi
HSCs. Furthermore, several innate immune cells, such
as B1 cells and ILC2P cells, accumulate in old mouse
BM as well as in skin/intestinal tissues. Such cells were
not considered in previous studies. Whether there are
lineage-biased HSCs in BM specific for innate immune
cells or not, and whether such HSCs are also increased
in aged mice, need to be determined. Lastly, although
the heterogeneity of both MSCs and ECs in BM tissue
were investigated recently using a single-cell technique,
the differentiation hierarchies of MSCs and ECs have
not yet been determined. Taken together, the detailed
cellular components and mechanisms of HSC niches
have not been sufficiently elucidated.
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